This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Addgene
product type :
cDNA
product name :
-24lacZ
catalog :
25422
citations: 1
Reference |
---|
Chen J, Love C, Goldhamer D. Two upstream enhancers collaborate to regulate the spatial patterning and timing of MyoD transcription during mouse development. Dev Dyn. 2001;221:274-88 pubmed
|
product information
Catalog Number :
25422
Product Name :
-24lacZ
article :
doi | 10.1002/dvdy.1138 |
id | 3441 |
pubmed_id | 11458388 |
bacterial resistance :
Ampicillin
cloning :
backbone | pPD46.21 | |||
backbone_mutation | ||||
backbone_origin | Fire et al., 1990 | |||
backbone_size | 6110 | |||
promoter | ||||
sequencing_primer_3 | ||||
sequencing_primer_5 | ||||
vector_types |
|
growth notes :
-24lacZ contains approximately 24 kb of 5' flanking sequences of the human MyoD gene, cloned upstream of the lacZ reporter gene in the vector pPD46.21 (Fire et al., 1990). MyoD flanking sequences were derived from the CAT reporter construct, -24CAT (Goldhamer et al., 1992), as follows. The unique XhoI site, which is just 3' of human sequences in -24CAT, was Klenow-filled and AscI linkers (New England Biolabs) were added by blunt-end ligation using standard methods. AscI linkers were also added to the unique SmaI site in the polylinker of pPD46.21. The 24-kb fragment was excised from -24CAT by digestion with SalI and AscI, purified by agarose gel electrophoresis and GENECLEAN Xbio-gene), and directionally cloned into pPD46.21 that had been similarly prepared. The resulting clone contains contiguous MyoD 5' flanking sequences from approximately 24 kb upstream to 170 bp downstream of the MyoD transcriptional start site (-37 relative to the start of translation).
origin :
37
pi :
|
resistance markers :
745 |
tags :
Unknown
company information
Addgene
490 Arsenal Way, Suite 100
Watertown, MA 02472
Watertown, MA 02472
info@addgene.org
https://www.addgene.org617.225.9000
headquarters: USA
questions and comments